Purpose: Perfluorocarbon liquids (PFCLs) are well tolerated in intraocular surgery, but chronic exposure can cause inflammation. PFCL leakage into the orbit without significant sequelae has been reported, but PFCL leakage into the preseptal subcutaneous tissues has not been described.
Methods: A case report is presented.
Results: A 46-year-old man presented with hand motion vision from a ruptured globe and retained intraocular foreign body. Intraoperatively, the foreign body could not be removed, and PFCL extravasated from the posterior globe rupture. Postoperative imaging revealed hyperdense material in the orbit, lids, and superficial adnexal tissues. The patient tolerated the retained PFCL, and imaging 10 months later demonstrated interval resorption. The patient eventually developed ocular siderosis and underwent transconjunctival orbitotomy with foreign body extraction. Two years following the initial injury, his vision remained stable at 20/40 without further sequelae.
Conclusions: PFCL is well tolerated in the extraocular space and may resorb with conservative management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976109 | PMC |
http://dx.doi.org/10.1177/2474126419899768 | DOI Listing |
Blood Coagul Fibrinolysis
October 2024
Hematology Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Nowadays, direct oral anticoagulants (DOACs) represent the gold standard for venous thromboembolism (VTE) treatment and VTE secondary prophylaxis; nevertheless, the percentage of elderly patients in major trials and literature data about DOACs usage for VTE secondary prophylaxis in the elderly are scant. Our retrospective study tried to evaluate low-dose DOACs efficacy and safety for elderly VTE secondary prophylaxis in a real-life setting. A cohort of 73 patients (≥ 75 years) considered at high risk of VTE recurrence was treated with apixaban 2.
View Article and Find Full Text PDFBlood
December 2024
Versiti Blood Research Institute, Milwaukee, Wisconsin, United States.
Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition. As patients with access to advanced CML care have an almost normal life expectancy, there is a perception that CML is a problem of the past, and one should direct research resources elsewhere. However, a closer look at the current CML landscape reveals a more nuanced picture.
View Article and Find Full Text PDFMembranes (Basel)
December 2024
Guangxi Key Laboratory of Information Materials, Guilin University of Electronic Technology, Guilin 541004, China.
Currently, the main limitations of Pd-coated Nb-TiFe dual-phase alloys include insufficient hydrogen permeability, susceptibility to hydrogen embrittlement (HE), and poor tolerance of HS poisoning. To address these issues, this study proposes a series of improvements. First, a novel NbTiFe alloy composed of a well-aligned Nb-TiFe eutectic was successfully prepared using directional solidification (DS) technology.
View Article and Find Full Text PDFMetabolites
December 2024
School of Food Science and Engineering, Foshan University, Foshan 528231, China.
Background: is a member of the lactic acid bacterium group commonly found in many salt-fermented foods. Strains of isolated from high-salinity environments have been shown to tolerate salt stress to some extent. However, the specific responses and mechanisms of under salt stress are not fully understood.
View Article and Find Full Text PDFMetabolites
December 2024
Hainan Key Laboratory of Crop Genetics and Breeding, Institute of Food Crops, Hainan Academy of Agricultural Sciences, Haikou 571100, China.
Green soybean ( (L.) Merrill) is a highly nutritious food that is a good source of protein and fiber. However, it is sensitive to low temperatures during the growing season, and enhancing cold tolerance has become a research hotspot for breeding improvement.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!